Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/16/2025

Management of JAK2 V617F Mutation

Diagnosis and Risk Stratification

  • The American Society of Hematology recommends that patients with a positive JAK2 V617F mutation require immediate risk stratification and tailored therapy based on their risk category, with high-risk patients (age ≥60 years or history of thrombosis) requiring phlebotomy, low-dose aspirin, and cytoreductive therapy 1, 2
  • The World Health Organization (WHO) diagnostic criteria for polycythemia vera (PV) include the presence of a JAK2 V617F mutation or a similar functional mutation, and either a hemoglobin level ≥18.5 g/dL in men or ≥16.5 g/dL in women, or the presence of endogenous erythroid colony growth in vitro 3
  • The European LeukemiaNet recommends that all patients with PV or essential thrombocythemia (ET) undergo regular monitoring for signs of disease progression, including blood counts, spleen size, and symptoms 4, 5

Treatment Algorithm

  • The National Comprehensive Cancer Network (NCCN) recommends that high-risk patients with PV receive phlebotomy to maintain a hematocrit <45%, low-dose aspirin (81-100 mg daily), and cytoreductive therapy with hydroxyurea or interferon-α 2, 4
  • The NCCN also recommends that low-risk patients with PV receive phlebotomy to maintain a hematocrit <45% and low-dose aspirin (81-100 mg daily), with cytoreductive therapy reserved for patients with platelet counts >1500 × 10⁹/L 2, 5
  • The European LeukemiaNet recommends that high-risk patients with ET receive cytoreductive therapy with hydroxyurea, and that low-risk patients with ET receive low-dose aspirin and be monitored regularly for signs of disease progression 4, 5

Special Clinical Situations

  • The American College of Obstetricians and Gynecologists (ACOG) recommends that pregnant women with PV or ET receive low-dose aspirin and be monitored regularly for signs of disease progression, with interferon-α preferred over hydroxyurea due to its lower risk of teratogenicity 2
  • The NCCN recommends that patients with a history of thrombosis receive anticoagulation therapy with a target INR of 2.0-3.0, in addition to their regular PV or ET therapy 5

Monitoring and Surveillance

  • The NCCN recommends that patients with PV or ET undergo regular monitoring every 3-6 months, including blood counts, spleen size, and symptoms, as well as annual monitoring of their JAK2 V617F mutation burden 1, 2
  • The European LeukemiaNet recommends that patients with PV or ET undergo bone marrow biopsy if they develop signs of disease progression, such as increasing spleen size, cytopenias, or constitutional symptoms 4, 5